Literature DB >> 32860594

Aspergillus fumigatus cholangitis in a patient with cholangiocarcinoma: case report and review of the literature.

Kathrin Rothe1, Sebastian Rasch2, Nina Wantia1, Alexander Poszler2, Joerg Ulrich2, Christoph Schlag2, Wolfgang Huber2, Roland M Schmid2, Dirk H Busch1,3, Tobias Lahmer4.   

Abstract

Aspergillus spp. cholangitis is an uncommon presentation of invasive aspergillosis. Only few cases are described in the literature affecting severely immunocompromised patients or patients following biliary surgery. Especially, invasive aspergillosis in non-haematological patients is associated with high mortality rates, caused by atypical presentations, which is associated with a delay in diagnosis and therapy. We report a 72-year-old man with primary diagnosis of cholangiocarcinoma and stent implantation by endoscopic retrograde cholangiopancreatography (ERCP) for biliary decompression who developed severe cholangitis with invasive aspergillosis. The patient had no history of prior hospitalisation, no immunosuppressive therapy and no preceding biliary surgery. Furthermore, in this exceptional case of extrapulmonary aspergillosis, there were no signs of pulmonary involvement. From the literature review, only three cases of Aspergillus cholangitis could be identified. Clinical manifestations of invasive aspergillosis can be variable and classical risk factors such as immunosuppression are not mandatorily present. Clinical awareness of these rare cases is of vital importance for initiation of correct therapy.

Entities:  

Keywords:  Aspergillus cholangitis; Extra-pulmonary aspergillosis; Liposomal amphotericin B

Mesh:

Year:  2020        PMID: 32860594      PMCID: PMC7851102          DOI: 10.1007/s15010-020-01487-4

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   7.455


  1 in total

1.  Small bowel infarction by Aspergillus.

Authors:  L Catalano; M Picardi; D Anzivino; L Insabato; R Notaro; B Rotoli
Journal:  Haematologica       Date:  1997 Mar-Apr       Impact factor: 9.941

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.